Investigational Drug Information for Defactinib
What is the development status for investigational drug Defactinib?
Defactinib is an investigational drug.
There have been 35 clinical trials for Defactinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 29th 2024.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Pancreatic Neoplasms. The leading clinical trial sponsors are Verastem, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.
There are two hundred and eighteen US patents protecting this investigational drug and four hundred and sixty-five international patents.
Summary for Defactinib
| US Patents | 218 |
| International Patents | 465 |
| US Patent Applications | 594 |
| WIPO Patent Applications | 198 |
| Japanese Patent Applications | 38 |
| Clinical Trial Progress | Phase 2 (2024-04-29) |
| Vendors | 63 |
Recent Clinical Trials for Defactinib
| Title | Sponsor | Phase |
|---|---|---|
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer | Verastem, Inc. | PHASE1 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer | M.D. Anderson Cancer Center | PHASE1 |
| Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | The Foundation for Barnes-Jewish Hospital | PHASE2 |
Clinical Trial Summary for Defactinib
Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib
US Patents for Defactinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Defactinib | ⤷ Start Trial | Use of inhibitors of Bruton'S tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Start Trial |
| Defactinib | ⤷ Start Trial | Gene fusions and gene variants associated with cancer | LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) | ⤷ Start Trial |
| Defactinib | ⤷ Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Start Trial |
| Defactinib | ⤷ Start Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Defactinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Defactinib | Australia | AU2011261185 | 2030-06-03 | ⤷ Start Trial |
| Defactinib | Australia | AU2015275321 | 2030-06-03 | ⤷ Start Trial |
| Defactinib | Australia | AU2018204179 | 2030-06-03 | ⤷ Start Trial |
| Defactinib | Australia | AU2020202752 | 2030-06-03 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
